Abstract 3166
Background
Aberrations in fibroblast growth factor receptors (FGFR) are common in multiple cancers, making them highly promising therapeutic targets. Optimal application of FGFR inhibitors requires a comprehensive understanding of the prevalence and types of FGFR mutations, which may vary significantly among ethnicities. Such analysis has not been conducted in Chinese pan-cancer. This study investigated the prevalence and the distribution of FGFR aberrations in Chinese cancer patients.
Methods
We screened genomic profiling results of plasma or tissue samples from 10,582 patients spanning 16 cancer types: lung, breast, gastric, hepatobiliary, pancreatic, soft tissue sarcoma, esophageal, ovarian, colorectal, head and neck, renal, endometrial, osteogenic sarcoma, cervical, melanoma and lymphoma.
Results
Of the 10,582 patients screened, we observed 745 patients with FGFR aberrations, revealing an overall prevalence of 7.03%. Approximately, 3.78% harbored FGFR amplification, 2.73% had other mutations and 0.53% had fusions. A majority (56.78%) of patients had FGFR1 aberrations, followed by 17.72%, 14.43% and 2.82% with FGFR3, FGFR2 and FGFR4 aberrations, respectively. Furthermore, 8.46% of patients with aberrations in more than 1 FGFR gene. The most common type of aberrations was amplification (53.69%), followed by other mutations (38.79%) and fusions (5.64%). Concurrent FGFR fusion and amplification occurred in 1.88% patients. Of the 16 cancer types, except for head and neck cancer, osteogenic sarcoma, renal carcinoma, and lymphoma, all other cancer types had FGFR aberrations detected with colorectal cancer (31.03%) having the highest prevalence. Other relatively commonly affected cancers included: gastric cancer (16.78%), breast cancer (14.27%) and esophageal cancer (12.68%). FGFR1 amplification was the most common genetic alteration in CRC, breast cancer and lung cancer. FGFR2 amplification was more commonly seen in gastric cancer. Of the patients with FGFR aberrations, 57 patients, spanning 9 cancer types, had fusions. Among them, breast cancer patients are more likely to have concurrent FGFR amplification than other cancer types (p < 0.001).
Conclusions
Our study provides a comprehensive view of FGFR aberrations in Chinese cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yang Gao.
Funding
Key Research and Development Program of Hunan province (2016JC2039).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract
1084 - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy
Presenter: Pauline Vaflard
Session: Poster Display session 3
Resources:
Abstract